Kunming Longjin Pharmaceutical Co., Ltd. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was CNY 71.05 million compared to CNY 102.78 million a year ago. Revenue was CNY 71.05 million compared to CNY 102.78 million a year ago.

Net loss was CNY 26.64 million compared to CNY 3.32 million a year ago. Basic loss per share from continuing operations was CNY 0.0665 compared to CNY 0.0083 a year ago. Diluted loss per share from continuing operations was CNY 0.0665 compared to CNY 0.0083 a year ago.